biotechs there are always opportunities in biotech, you have to look for them which brings me to karuna therapeuticsy stage biotech working on medications for people's psychiatric and neurologic conditions. they're studying schizophrenia and dementia and psychosis existing antipsychotic drugs have unbelievably horrible side effects. unlike most biotechs, karuna hasn't dropped in the market it's up 21%. in the past month it's pulled back like many other stocks even though management gave a bullish presentation in november could this be a buying opportunity? let's check in with dr. steve paul he's the chairman and ceo of karuna thir a put particulars. welcome to "mad money." >> thanks for having me. appreciate it. >> dr. ball, our viewers don't know karuna. this is your first visit what are you doing for some very difficult illnesses. >> thanks, jim karuna is a clinical stage psych focused, cns focused biotech company developing what we believe will be a best in class potentially game-changing treatment for schizophrenia and psychotic disorders in general as you probably know, schizophrenia is a very